Protagonist Therapeutics Net Income 2015-2021 | PTGX

Protagonist Therapeutics net income from 2015 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Protagonist Therapeutics Annual Net Income
(Millions of US $)
2020 $-66
2019 $-77
2018 $-39
2017 $-37
2016 $-38
2015 $-15
2014 $-11
Protagonist Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-31
2021-03-31 $-24
2020-12-31 $-19
2020-09-30 $-8
2020-06-30 $-19
2020-03-31 $-20
2019-12-31 $-18
2019-09-30 $-16
2019-06-30 $-29
2019-03-31 $-14
2018-12-31 $-14
2018-09-30 $-9
2018-06-30 $-9
2018-03-31 $-8
2017-12-31 $-3
2017-09-30 $-5
2017-06-30 $-15
2017-03-31 $-14
2016-12-31 $-11
2016-09-30 $-7
2016-06-30 $-7
2016-03-31 $-12
2015-12-31
2015-09-30 $-3
2015-06-30 $-3
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.515B $0.029B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.527B 7.92
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.184B 20.63
Biohaven Pharmaceutical Holding (BHVN) United States $8.967B 0.00
Emergent Biosolutions (EBS) United States $2.590B 6.25
Arcus Biosciences (RCUS) United States $2.362B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.929B 0.00
Myovant Sciences (MYOV) United Kingdom $1.832B 0.00
Zymeworks (ZYME) Canada $1.055B 0.00
Ambrx Biopharma (AMAM) United States $0.463B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.67